car-t & bispecific antibodies in second-line dlbcl
Published 2 years ago • 252 plays • Length 2:34Download video MP4
Download video MP3
Similar videos
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
2:38
weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
-
6:59
will bispecific antibodies challenge car t-cell therapy in follicular lymphoma? - medpage today
-
6:02
car-t vs. bites in b-cell malignancies
-
3:46
battling relapsed diffuse large b-cell lymphoma (dlbcl) - sam's story
-
1:44
bispecific antibodies vs car-t cells in dlbcl: the benefit of car-t therapy
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
12:15
car-t vs bispecific antibodies for lymphoma
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
1:40
current & future outlooks on car-t therapy & bispecific antibodies in follicular lymphoma
-
4:27
the possibility of combining car-t therapy and bispecific antibodies in the treatment of nhl
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:22
combining car-ts & bispecific antibodies
-
6:38
the sequencing of cd19-targeting car-ts and cd20-targeting bispecifics in dlbcl
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
2:05
strategies to implement car-t in dlbcl
-
2:39
the role of bispecific antibodies in the treatment landscape for r/r dlbcl
-
1:04
bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents